-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Sodium Cytidine Diphosphate Choline Injection (4 mL: 0.5 g) from Shijiazhuang Sihua Pharmaceutical Group Has Been Approved
Category:
发布时间：2023-06-13
【概要描述】
On June 13, the Class 3 chemical drug sodium citicoline injection (4 mL: 0.5 g) developed and submitted for approval by Shijiazhuang Sihua Pharmaceutical Group received drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
On June 13, the Class 3 chemical drug sodium citicoline injection (4 mL: 0.5 g) developed and submitted for approval by Shijiazhuang Sihua Pharmaceutical Group received drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
According to reports, sodium citicoline injection is primarily used for consciousness disorders following acute traumatic brain injury and brain surgery.
Over the past two years, Shijiazhuang Sihua Pharmaceutical has been driven by innovation to promote high-quality corporate development, with its R&D and innovation efforts entering a period of concentrated成果. To date this year, the company has launched 32 new products, and its R&D efficiency continues to rank among the highest in the national pharmaceutical industry.
Meanwhile, the cumulative number of generic drugs that have passed the quality and therapeutic equivalence evaluation (or are deemed to have passed such evaluation) has reached 50 varieties encompassing 65 specifications, continuously injecting new momentum into enterprises’ high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091